U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07382817) titled 'Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms' on Jan. 30.
Brief Summary: The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell lymphoma that is relapsed or refractory. The safety and possible side effects of JV-394 will also be studied.
Study Start Date: Feb. 16
Study Type: INTERVENTIONAL
Condition:
Neoplasms
Intervention:
DRUG: JV-394
Given by infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content S...